Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34470774.
- Also identified by DOI 10.1158/1078-0432.CCR-21-2574 and PMC identifier 8563411.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cellular therapies have demonstrated limited efficacy thus far in acute myeloid leukemia (AML). A recent study shows that mTOR complex 1 activation downregulated CXCR4 reducing marrow infiltration of EpCAM-targeting chimeric antigen receptor (CAR) T-cells in AML. Abrogating mTOR signaling by cotreatment with mTOR inhibitors during IL2-mediated <i>ex vivo</i> expansion upregulated CXCR4 and bolstered bone marrow migration and AML elimination by CAR T-cells.<i>See related article by Nian et al., p. 6026</i>.
Medical subject headings
- Leukemia, Myeloid, Acute
- Receptors, Chimeric Antigen